Please login to the form below

Not currently logged in
Email:
Password:

oral semaglutide

This page shows the latest oral semaglutide news and features for those working in and with pharma, biotech and healthcare.

Novo’s oral diabetes drug hits the mark again

Novo’s oral diabetes drug hits the mark again

The 26-week phase IIIa trial, also known as PIONEER 5, investigated oral semaglutide in 324 patients with type 2 diabetes and who have a kidney-impairment, a serious diabetes complication. ... in people with type 2 diabetes and moderate renal impairment,

Latest news

More from news
Approximately 3 fully matching, plus 8 partially matching documents found.

Latest Intelligence

  • Oral biologics delivery still elusive Oral biologics delivery still elusive

    Novo Nordisk is also working with another specialist on oral delivery for protein drugs - Emisphere Technologies - that has applied its Eligen technology to develop an oral version of semaglutide, a ... rarely as once a quarter for example, which makes

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Swordfish Advertising

At Swordfish Advertising, we believe building an effective brand shouldn't be stressful. Don't get us wrong; it takes blood, sweat...

Latest intelligence

Ali Frederic Ben-Amor
Tackling a formidable foe
Ali Frederic Ben-Amor tells how Merck is taking the fight to multiple sclerosis...
Geoff
Cancer care – the power of new technologies
With patient numbers set to soar, how can we make a difference?...
image 1
Redefining communications excellence
How to be heard in today’s multichannel, multistakeholder, multimedia world...

Infographics